Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
19 sept. 2023 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic...
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
19 sept. 2023 07h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social...
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
18 sept. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan...
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
06 sept. 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine...
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
06 sept. 2023 07h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today revealed new nationwide survey results indicating...
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
05 sept. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the...
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
22 août 2023 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Onsite Women’s Health, a leading national provider of...
Myriad Genetics to Host Investor Day on September 19, 2023
17 août 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day at the newly constructed Dr....
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
15 août 2023 07h05 HE
|
Myriad Genetics, Inc.
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
08 août 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, part of the...